Oryzon Genomics

Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
  • TickerORY
  • ISINES0167733015
  • ExchangeMadrid Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySpain

Analysts

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - ORYZON GENOMICS : Vafidemstat shows promise in BPD and ADHD - BUY, TP €8,8

Dr Jonas Peciulis

Oryzon Genomics - First vafidemstat efficacy data

In April 2019, Oryzon released the results from the first two cohorts in the Phase II REIMAGINE trial, namely borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD). The datasets included the first efficacy results, which demonstrated vafidemstat’s potential in aggression management in these patients. REIMAGINE is a basket trial, enrolling patients with two neurodegenerative and three psychiatric diseases, hence the cohorts were small (six patients each). All primary and secondary endpoints were met with high statistical significance, which prompted Oryzon to...

Dr Jonas Peciulis

Oryzon Genomics - A year of data readouts

Oryzon has a total of five Phase II studies ongoing with its two lead assets iadademstat (formerly ORY-1001) and vafidemstat (formerly ORY-2001), which are all expected to have preliminary data readouts in 2019. In November 2018, the company announced the first patients had been recruited in to the iadademstat Phase IIa small cell lung cancer (CLEPSIDRA) and acute myeloid leukaemia (ALICE) studies. A scientific paper was recently published by a third party in Science Signalling, which has revealed a potential mechanism of action of iadademstat (ORY-1001) in pre-clinical SCLC models; this is su...

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - ORYZON GENOMICS : Vafidemstat shows promise in BPD and ADHD - BUY, TP €8,8

Dr Jonas Peciulis

Oryzon Genomics - First vafidemstat efficacy data

In April 2019, Oryzon released the results from the first two cohorts in the Phase II REIMAGINE trial, namely borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD). The datasets included the first efficacy results, which demonstrated vafidemstat’s potential in aggression management in these patients. REIMAGINE is a basket trial, enrolling patients with two neurodegenerative and three psychiatric diseases, hence the cohorts were small (six patients each). All primary and secondary endpoints were met with high statistical significance, which prompted Oryzon to...

Dr Jonas Peciulis

Oryzon Genomics - A year of data readouts

Oryzon has a total of five Phase II studies ongoing with its two lead assets iadademstat (formerly ORY-1001) and vafidemstat (formerly ORY-2001), which are all expected to have preliminary data readouts in 2019. In November 2018, the company announced the first patients had been recruited in to the iadademstat Phase IIa small cell lung cancer (CLEPSIDRA) and acute myeloid leukaemia (ALICE) studies. A scientific paper was recently published by a third party in Science Signalling, which has revealed a potential mechanism of action of iadademstat (ORY-1001) in pre-clinical SCLC models; this is su...

Dr Jonas Peciulis

Oryzon Genomics - Ramping up R&D activity; catalysts in 2019

The €13m (gross) private placement announced on 30 October 2018 will support Oryzon’s expanding R&D programme with a total of five clinical trials now underway. Two new Phase IIa trials with iadademstat (formerly ORY-1001) are starting in acute myeloid leukaemia (AML) (ALICE trial) and small cell lung cancer (SCLC) (CLEPSIDRA trial). Results from another two Phase IIa studies with vafidemstat (formerly ORY-2001) in Alzheimer’s disease (AD) patients (ETHERAL) and multiple sclerosis (MS) patients (SATEEN) are due to report results in H219. Before that, interim results from the innovative design ...

Martial Descoutures ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Oryzon Genomics : Une nouvelle vague - ACHAT ; OC 9.3€

Nous initions ce matin la couverture avec une opinion ACHAT et un objectif de cours de 9,3€. ORYZON est une Biotech espagnole spécialisée dans les traitements de cancers ou de troubles neurodégénératifs. Basés sur sa plateforme épigénétique (système de régulation contrôlant l'expression des gènes), les deux produits phares du groupe ORY1001 et ORY2001 sont actuellement en phase IIa dans 4 indications : Alzheimer, Sclérose en plaques, SCLC et la LAM. Les premiers résultats intermédiaires sont attendus mi 2019.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch